CN103467771A - Preparation method and application of marine organism active hemostasis dressing - Google Patents
Preparation method and application of marine organism active hemostasis dressing Download PDFInfo
- Publication number
- CN103467771A CN103467771A CN2013104344244A CN201310434424A CN103467771A CN 103467771 A CN103467771 A CN 103467771A CN 2013104344244 A CN2013104344244 A CN 2013104344244A CN 201310434424 A CN201310434424 A CN 201310434424A CN 103467771 A CN103467771 A CN 103467771A
- Authority
- CN
- China
- Prior art keywords
- preparation
- bleeding
- wound
- chitosan
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000023597 hemostasis Effects 0.000 title abstract description 11
- 238000003756 stirring Methods 0.000 claims abstract description 40
- 229920001661 Chitosan Polymers 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000000839 emulsion Substances 0.000 claims abstract description 15
- 238000005406 washing Methods 0.000 claims abstract description 13
- 239000012188 paraffin wax Substances 0.000 claims abstract description 12
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 11
- 238000004945 emulsification Methods 0.000 claims abstract description 10
- 230000035876 healing Effects 0.000 claims abstract description 6
- 238000004132 cross linking Methods 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 19
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 17
- 235000010413 sodium alginate Nutrition 0.000 claims description 17
- 239000000661 sodium alginate Substances 0.000 claims description 17
- 229940005550 sodium alginate Drugs 0.000 claims description 17
- 239000012153 distilled water Substances 0.000 claims description 13
- 230000000844 anti-bacterial effect Effects 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- 230000018044 dehydration Effects 0.000 claims description 7
- 238000006297 dehydration reaction Methods 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 7
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 238000006116 polymerization reaction Methods 0.000 claims description 6
- 231100000241 scar Toxicity 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 230000002364 anti-haemorrhagic effect Effects 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 230000008520 organization Effects 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 230000000472 traumatic effect Effects 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 230000000740 bleeding effect Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- VFKZECOCJCGZQK-UHFFFAOYSA-M 3-hydroxypropyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCO VFKZECOCJCGZQK-UHFFFAOYSA-M 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003114 blood coagulation factor Substances 0.000 abstract 1
- 229940019700 blood coagulation factors Drugs 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- 239000003431 cross linking reagent Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000007789 sealing Methods 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 238000007711 solidification Methods 0.000 abstract 1
- 230000008023 solidification Effects 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 21
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 230000029663 wound healing Effects 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000003828 vacuum filtration Methods 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000002439 hemostatic effect Effects 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 description 2
- 206010061926 Purulence Diseases 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 230000000025 haemostatic effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000002910 structure generation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940035658 visco-gel Drugs 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a preparation method and application of a marine organism active hemostasis dressing. The preparation method comprises the steps of adding equal sodium alga acid solution while stirring a water solution comprising hydroxypropyl trimethyl ammonium chloride chitosan and/or an acetum of chitosan so as to obtain a liquor 1, taking an emulsion comprising paraffin as a liquor 2, mixing the liquor 1 and the liquor 2 according to the proportion of (2-3):5 and stirring uniformly so as to obtain a stable emulsification system, adding a cross-linking agent calcium chloride solution for cross-linking and solidifying the emulsification system, then washing, dewatering and drying so as to obtain the marine organism active hemostasis dressing. The materials of the prepared microballoon product have good biocompatibility and biodegradability as well as special effects of resisting bacterium, stopping bleeding, and promoting healing, when being contacted with a wound, the cross-linking and solidification product can rapidly absorb moisture in blood and concentrate blood platelets and blood coagulation factors into sticky gel, thus effectively sealing the bleeding wound and enhancing the hemostasis performance of the microballoon material, and therefore, the marine organism active hemostasis dressing is stable, efficient and environment-friendly.
Description
Affiliated technical field
The present invention relates to a kind of bleeding-stopping dressing, particularly relate to a kind of preparation method and its usage of marine bioactivity bleeding-stopping dressing.
Background technology
Chitosan is that content is only second to cellulosic second largest natural biological macromolecular material, there are nontoxic, good biocompatibility, anti-inflammatory, anti, antibacterial, wound healing and moisture-absorbing moisture-keeping and easy many excellent properties such as degraded, can be degraded to the available monose of body by N,O-Diacetylmuramidase, show good biodegradability, and play Blood clotting by number of ways.Quaternary Ammonium Salt of Chitosan is a kind of cats product, positively charged in water, can adsorb and the microorganism surface, form micelle, and progressively infiltrate cytoplasmic lipoid layer and protein, thus the permeability of change cytolemma, be that entocyte leaks, cause microbial death; Also can make the structure generation sex change of albumen and enzyme, the metabolism of destroy microorganisms, kill microorganism simultaneously.Lalgine is the natural polyanionic polysaccharide extracted in brown alga, it has similar performance to chitosan, when sodium alginate and calcium chloride crosslinked after, can generate alginate calcium, the alginate calcium generated is with after the purulence blood on wound contacts, can with body fluid in sodium ion generation ion-exchange, be converted into the gel of stickiness when discharging calcium ion.Large quantity research shows, after interacting by certain physics or chemical mode with alginate calcium when chitosan, can form that short more effect is stronger, antibacterial effect better, haemostatic effect is better.The composite marine biomaterial that mechanical property is more excellent.
Wound hemorrhage is one of important illness of harm humans health and lives safety, and no matter War And Peace period, unmanageable profuse bleeding is to cause wounded's main causes of death.The war wound caused owing to losing blood in war is cut personnel larger proportion, and approximately 50% person killed in action is before delivering to dressing station according to statistics, because of severe loss of blood death in several minutes.Injured hemorrhage also very common in peacetime various unexpected incidents.It is exactly the typical case that China's traffic accident and the casualties are continuous ascendant trend.Hemostasis is significant to reducing disability and injures and deaths simply, fast and effectively.Traditional dressing is as the dressing of all kinds of gauze type, and major function is to prevent wound infection, the protection surface of a wound, but little to the effect that promotes wound healing, even also can affect wound healing, and the effect surface of a wound that can not be fully effective.Therefore novel hemostatic material and apparatus are the wound hemostasis urgent problems, are subject to the great attention of countries in the world medical science and military medicine.Along with to the going deep into of researching wound healing, the purpose of using dressing is far from for flap coverage, hemostatic and antibacterial and promote healing to become the certainty of hemostatic material development.Existing hemostatic material is confined to simple hemostasis more, but it is also fewer that anti-infective, promoting healing, promotion tissue repair, prevention are adhered, reduce the research of the aspects such as scar.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of preparation method of marine bioactivity bleeding-stopping dressing, and this bleeding-stopping dressing has efficient anthemorrhagic performance to the surface of a wound, and have antibacterial, promote that tissue repair, prevention are adhered, biodegradability.
For solving the problems of the technologies described above, the preparation method of this marine bioactivity bleeding-stopping dressing is:
To contain the acetum of the aqueous solution of HACC and/or chitosan in the situation that stir and add the sodium alginate soln of equivalent as 1 liquid, to contain the emulsion of paraffin as 2 liquid, 1 liquid and 2 liquid are become to stable emulsification system according to the ratio mixing and stirring of 2～3:5, add the linking agent calcium chloride solution to make its crosslinking curing, then be drying to obtain by washing dehydration.
Described HACC and chitosan solution have following general formula:
Wherein, polymerization degree n is between 300～2000, and relative molecular mass is 8.4 * 10
4～5.6 * 10
5between;
The general structure of described Lalgine sodium salt is as follows:
Wherein, polymerization degree n is between 180-930, and relative molecular mass is 3.2 * 10
4～2.5 * 10
5between.
The compound method of described HACC and chitosan-acetic acid solution is: the HACC of equivalent is dissolved in distilled water, be mixed with the aqueous solution that mass percentage concentration is 1.6～2.4%, it is in 1～2:100 acetum that chitosan is joined to volume ratio, stirs and is mixed with the colloidal solution that mass percentage concentration is 1.6～2.4%.
The mass percentage concentration of described sodium alginate soln is 1～2%, during preparation, is sodium alginate is entered in distilled water, is mixed with micro-yellow milky solution.
The compound method of the emulsified soln of described paraffin is: will the class of department 80, tween 80 and stearic acid be mixed into emulsifying agent according to the mass ratio of 9:9:1～3, and by emulsifying agent and whiteruss, the mass ratio according to 12～13:125 mixes, and stirs into O(water under 72～78 ℃)/W(oil) emulsion.
The massfraction of linking agent calcium chloride is 1.6%～3.2%, and it joins in emulsification system liquid according to the volume ratio with emulsification system 1:12～18, and the temperature of reaction is 70～80 ℃, and the reaction times is 50～60min.
Described washing is washings washing, and described washings is Virahol, and except de-emulsifier and paraffin, the translucent microballoon of washing gel carries out gradient with alcohol again and is dehydrated into silt shape solid-state-microspherical, then carries out vacuum-drying and become powder to get final product.
Purposes of the present invention: for the various traumatic surface of a wound, the antibacterial anti hemorrhagic of the surface of a wound such as mucous membrane, the uterine neck surface of a wound, empyrosis wound surface, operative incision, ulcer, bedsore, promotion organization healing, prevent to be adhered and to reduce scar.
The present invention has following advantage:
1. chitosan has the biological activitys such as good biocompatibility and anti-inflammatory, anti, antibacterial, wound healing, can be degraded to the available monose of body by N,O-Diacetylmuramidase, show good biodegradability, and play Blood clotting by number of ways.The chitosan quaternary ammonium salt sterilization effect added is better than chitosan, and biocompatibility is better, has increased the antibacterial ability of particulate.
2. generate the Ah-ACMS complex microsphere after emulsification and cross linked, and alginate calcium has good biocompatibility and biodegradability, and antibacterial, hemostasis, short more, alleviate the specific function such as scar.The Lalgine calcium salt is with after purulence blood on wound contacts, the Lalgine calcium salt can with body fluid in sodium ion generation ion-exchange, be converted into the gel of stickiness when discharging calcium ion, a large amount of assemblies of wound surface calcium ion can be accelerated surface of a wound hemostasis.
3. the microballoon be prepared from after emulsification and cross linked, particle diameter is tiny, there is larger specific surface area, increase the contact area of material and blood, water absorption and swelling becomes the viscogel shape fast, be attached to the surface of a wound, the capillary vessel that the shutoff surface of a wound breaks, strengthened the performance of the promotion erythrocyte aggregation of micro-sphere material itself, keep or the intrinsic anthemorrhagic performance of expansion biomaterial itself, and form water gel at the surface of a wound after hemostasis, the energy wound healing, simultaneously soft, moistening gelinite provides moist repairing environment for wound, accelerate the growth of granulation tissue and the formation of epithelium, thereby make this dressing stronger than the short more effect of other similar dressing, antibacterial effect is better, haemostatic effect is better, mechanical property is more excellent.
4. the preparation technology of the biological bleeding-stopping dressing of the present invention is simple, and material is easy to get, and is applicable to carry out suitability for industrialized production, has a extensive future.
Embodiment
Below in conjunction with specific embodiment, the present invention is described in further detail:
Embodiment 1
Take 18.1g department class 80,18.1g tween 80,2.0g stearic acid and join in the 500ml whiteruss, stir into O(water under 72 ℃)/(oil) W emulsion.Get the 0.8g HACC and be added in the 50ml distilled water, the 0.8g chitosan is dissolved in the acetum that the 50ml volume fraction is 1%, and both mix.The 1.2g sodium alginate is added in the 100ml distilled water, and the salts solution of chitosan is joined to sodium alginate soln fully stirs into stable colloidal solution, then join in the emulsion of paraffin rapid stirring 25 minutes, stirring velocity 800-1000 rev/min.Add again the calcium chloride solution 40ml that massfraction is 1.6%, maintain the temperature at 72 ℃, stirring at low speed 50 minutes, stirring velocity 80-100 rev/min.Mixed solution is fallen to vacuum filtration in core.By 100ml washed with isopropyl alcohol 3 times, then use respectively 30%, 50%, 70%, 100% gradient alcohol dehydration, vacuum-drying becomes powder.
Embodiment 2
Take 18.7g department class 80,18.7g tween 80,4.2g stearic acid and join in the 500ml whiteruss, stir into O(water under 75 ℃)/(oil) W emulsion.Get the 1.0g HACC and be added in the 50ml distilled water, the 1.0g chitosan is dissolved in the acetum that the 50ml volume fraction is 1%, and both mix.The 1.5g sodium alginate is added in the 100ml distilled water, and the salts solution of chitosan is joined to sodium alginate soln fully stirs into stable colloidal solution, then join in the emulsion of paraffin rapid stirring 30 minutes, stirring velocity 800-1000 rev/min.Add again the calcium chloride solution 40ml that massfraction is 2.0%, maintain the temperature at 75 ℃, stirring at low speed 55 minutes, stirring velocity 80-100 rev/min.Mixed solution is fallen to vacuum filtration in core.By 100ml washed with isopropyl alcohol 3 times, then use respectively 30%, 50%, 70%, 100% gradient alcohol dehydration, vacuum-drying becomes powder.
Embodiment 3
Take 18.4g department class 80,18.4g tween 80,6.1g stearic acid and join in the 500ml whiteruss, stir into O(water under 78 ℃)/(oil) W emulsion.Get the 1.2g HACC and be added in the 50ml distilled water, the 1.2g chitosan is dissolved in the acetum that the 50ml volume fraction is 1%, and both mix.The 1.8g sodium alginate is added in the 100ml distilled water, and the salts solution of chitosan is joined to sodium alginate soln fully stirs into stable colloidal solution, then join in the emulsion of paraffin rapid stirring 45 minutes, stirring velocity 800-1000 rev/min.Add again the calcium chloride solution 40ml that massfraction is 2.4%, maintain the temperature at 80 ℃, stirring at low speed 1h, stirring velocity 80-100 rev/min.Mixed solution is fallen to vacuum filtration in core.By 100ml washed with isopropyl alcohol 3 times, then use respectively 30%, 50%, 70%, 100% gradient alcohol dehydration, vacuum-drying becomes powder.
Embodiment 4
Take 18.7g department class 80,18.7g tween 80,4.2g stearic acid and join in the 500ml whiteruss, stir into O(water under 75 ℃)/(oil) W emulsion.Getting the 2.0g HACC is dissolved in the 100ml distilled water and mixes, the 1.5g sodium alginate is added in the 100ml distilled water, and the salts solution of chitosan is joined to sodium alginate soln fully stir into stable colloidal solution, join again in the emulsion of paraffin, rapid stirring 30 minutes, stirring velocity 800-1000 rev/min.Adding massfraction is 2.0% calcium chloride solution 40ml again, maintains the temperature at 75 ℃, stirring at low speed 55 minutes, stirring velocity 80-100 rev/min.Mixed solution is fallen to vacuum filtration in core.By 100ml washed with isopropyl alcohol 3 times, then use respectively 30%, 50%, 70%, 100% gradient alcohol dehydration, vacuum-drying becomes powder.
Embodiment 5
Take 18.7g department class 80,18.7g tween 80,4.2g stearic acid and join in the 500ml whiteruss, stir into O(water under 75 ℃)/(oil) W emulsion.Getting the 2.0g chitosan is added in the acetum that the 100ml volume fraction is 1%.The 1.5g sodium alginate is added in the 100ml distilled water, and the salts solution of chitosan is joined to sodium alginate soln fully stirs into stable colloidal solution, then join in the emulsion of paraffin rapid stirring 30 minutes, stirring velocity 800-1000 rev/min.Adding massfraction is 2.0% calcium chloride solution 40ml again, maintains the temperature at 75 ℃, stirring at low speed 55 minutes, stirring velocity 80-100 rev/min.Mixed solution is fallen to vacuum filtration in core.By 100ml washed with isopropyl alcohol 3 times, then use respectively 30%, 50%, 70%, 100% gradient alcohol dehydration, vacuum-drying becomes powder.
HACC of the present invention and chitosan solution have following general formula:
or
Wherein, polymerization degree n is between 300～2000, and relative molecular mass is 8.4 * 10
4～5.6 * 10
5between.
The general structure of Lalgine sodium salt of the present invention is as follows:
Wherein, polymerization degree n is between 180-930, and relative molecular mass is 3.2 * 10
4～2.5 * 10
5between.
Purposes of the present invention: for the various traumatic surface of a wound, the antibacterial anti hemorrhagic of the surface of a wound such as mucous membrane, the uterine neck surface of a wound, empyrosis wound surface, operative incision, ulcer, bedsore, promotion organization healing, prevent to be adhered and to reduce scar.
Claims (8)
1. the preparation method of a marine bioactivity bleeding-stopping dressing, it is characterized in that containing the acetum of the aqueous solution of HACC and/or chitosan in the situation that stir and add the sodium alginate soln of equivalent as 1 liquid, to contain the emulsion of paraffin as 2 liquid, 1 liquid and 2 liquid are become to stable emulsification system according to the ratio mixing and stirring of 2～3:5, add the linking agent calcium chloride solution to make its crosslinking curing, then be drying to obtain by washing dehydration.
2. the preparation method of marine bioactivity bleeding-stopping dressing as claimed in claim 1 is characterized in that described HACC and chitosan solution have following general formula:
Wherein, polymerization degree n is between 300～2000, and relative molecular mass is 8.4 * 10
4～5.6 * 10
5between;
The general structure of described Lalgine sodium salt is as follows:
Wherein, polymerization degree n is between 180-930, and relative molecular mass is 3.2 * 10
4～2.5 * 10
5between.
3. the preparation method of marine bioactivity bleeding-stopping dressing as claimed in claim 1, the compound method that it is characterized in that described HACC and chitosan-acetic acid solution is: the HACC of equivalent is dissolved in distilled water, be mixed with the aqueous solution that mass percentage concentration is 1.6～2.4%, it is in 1～2:100 acetum that chitosan is joined to volume ratio, stirs and is mixed with the colloidal solution that mass percentage concentration is 1.6～2.4%.
4. the preparation method of marine bioactivity bleeding-stopping dressing as claimed in claim 1, is characterized in that the mass percentage concentration of described sodium alginate soln is 1～2%, during preparation, is that sodium alginate is entered in distilled water, is mixed with micro-yellow milky solution.
5. the preparation method of marine bioactivity bleeding-stopping dressing as claimed in claim 1, the compound method that it is characterized in that the emulsified soln of described paraffin is: will the class of department 80, tween 80 and stearic acid be mixed into emulsifying agent according to the mass ratio of 9:9:1～3, and by emulsifying agent and whiteruss, the mass ratio according to 12～13:125 mixes, and stirs into O(water under 72～78 ℃)/W(oil) emulsion.
6. the preparation method of marine bioactivity bleeding-stopping dressing as claimed in claim 1, the massfraction that it is characterized in that linking agent calcium chloride is 1.6%～3.2%, it joins in emulsification system liquid according to the volume ratio with emulsification system 1:12～18, the temperature of reaction is 70～80 ℃, and the reaction times is 50～60min.
7. the preparation method of marine bioactivity bleeding-stopping dressing as claimed in claim 1, it is characterized in that described washing is the washings washing, described washings is Virahol, except de-emulsifier and paraffin, washing gel translucent microballoon carries out gradient with alcohol again and is dehydrated into silt shape solid-state-microspherical, then carries out vacuum-drying and become powder to get final product.
8. the purposes of a marine bioactivity bleeding-stopping dressing, is characterized in that for the various traumatic surface of a wound, and the antibacterial anti hemorrhagic of the surface of a wound such as mucous membrane, the uterine neck surface of a wound, empyrosis wound surface, operative incision, ulcer, bedsore, promotion organization healing, prevent to be adhered and to reduce scar.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310434424.4A CN103467771B (en) | 2013-09-23 | 2013-09-23 | A kind of preparation method and its usage of marine bioactivity bleeding-stopping dressing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310434424.4A CN103467771B (en) | 2013-09-23 | 2013-09-23 | A kind of preparation method and its usage of marine bioactivity bleeding-stopping dressing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103467771A true CN103467771A (en) | 2013-12-25 |
| CN103467771B CN103467771B (en) | 2016-03-16 |
Family
ID=49792826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310434424.4A Expired - Fee Related CN103467771B (en) | 2013-09-23 | 2013-09-23 | A kind of preparation method and its usage of marine bioactivity bleeding-stopping dressing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103467771B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104998293A (en) * | 2015-08-17 | 2015-10-28 | 青岛卫辽医用生物材料有限公司 | Styptic powder |
| CN105031708A (en) * | 2015-08-25 | 2015-11-11 | 东莞市达庆医疗器械有限公司 | Rapid hemostatic powder for injury and preparation method of rapid hemostatic powder |
| CN105169460A (en) * | 2015-10-26 | 2015-12-23 | 广东泰宝医疗科技股份有限公司 | Magnetically therapeutic antibacterial haemostatic wound dressing and preparation method thereof |
| CN107335091A (en) * | 2017-08-31 | 2017-11-10 | 河南汇博医疗股份有限公司 | A kind of long acting antibiotic hydrogel and preparation method thereof |
| CN108126236A (en) * | 2017-12-20 | 2018-06-08 | 浙江科技学院 | A kind of medicine coating material and preparation method thereof |
| CN108744022A (en) * | 2018-07-06 | 2018-11-06 | 中国热带农业科学院农产品加工研究所 | A kind of functionality absorbable hemostatic powder and preparation method thereof |
| CN109364288A (en) * | 2018-11-26 | 2019-02-22 | 温州生物材料与工程研究所 | Hole-hole composite micro-nano structure polysaccharide microsphere is in the purposes for preparing bleeding-stopping dressing |
| CN110180018A (en) * | 2019-05-24 | 2019-08-30 | 武汉理工大学 | A kind of preparation method of calcic alginate/chitosan hemostatic microsphere |
| CN111632188A (en) * | 2020-06-09 | 2020-09-08 | 湖北精耕生物工程有限公司 | Seaweed polysaccharide composite biological matrix dressing and preparation method thereof |
| CN112755239A (en) * | 2020-12-08 | 2021-05-07 | 上海市肿瘤研究所 | Composite porous microsphere and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850111A (en) * | 2006-02-28 | 2006-10-25 | 中国人民解放军第二军医大学 | Biodegradeable hemostasis powder |
| CN101613420A (en) * | 2009-08-06 | 2009-12-30 | 浙江澳兴生物科技有限公司 | A kind of preparation method of 2-HACC |
| CN101735339A (en) * | 2010-01-12 | 2010-06-16 | 浙江理工大学 | Reactive chitosan derivative and preparation method thereof |
-
2013
- 2013-09-23 CN CN201310434424.4A patent/CN103467771B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850111A (en) * | 2006-02-28 | 2006-10-25 | 中国人民解放军第二军医大学 | Biodegradeable hemostasis powder |
| CN101613420A (en) * | 2009-08-06 | 2009-12-30 | 浙江澳兴生物科技有限公司 | A kind of preparation method of 2-HACC |
| CN101735339A (en) * | 2010-01-12 | 2010-06-16 | 浙江理工大学 | Reactive chitosan derivative and preparation method thereof |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104998293A (en) * | 2015-08-17 | 2015-10-28 | 青岛卫辽医用生物材料有限公司 | Styptic powder |
| CN105031708A (en) * | 2015-08-25 | 2015-11-11 | 东莞市达庆医疗器械有限公司 | Rapid hemostatic powder for injury and preparation method of rapid hemostatic powder |
| CN105031708B (en) * | 2015-08-25 | 2018-03-23 | 东莞市达庆医疗器械有限公司 | A kind of wound rapid hemostasis powder and preparation method thereof |
| CN105169460B (en) * | 2015-10-26 | 2018-09-25 | 广东泰宝医疗科技股份有限公司 | A kind of magnetic therapy antibacterial anti hemorrhagic dressing and preparation method thereof |
| CN105169460A (en) * | 2015-10-26 | 2015-12-23 | 广东泰宝医疗科技股份有限公司 | Magnetically therapeutic antibacterial haemostatic wound dressing and preparation method thereof |
| CN107335091A (en) * | 2017-08-31 | 2017-11-10 | 河南汇博医疗股份有限公司 | A kind of long acting antibiotic hydrogel and preparation method thereof |
| CN108126236A (en) * | 2017-12-20 | 2018-06-08 | 浙江科技学院 | A kind of medicine coating material and preparation method thereof |
| CN108744022A (en) * | 2018-07-06 | 2018-11-06 | 中国热带农业科学院农产品加工研究所 | A kind of functionality absorbable hemostatic powder and preparation method thereof |
| CN109364288A (en) * | 2018-11-26 | 2019-02-22 | 温州生物材料与工程研究所 | Hole-hole composite micro-nano structure polysaccharide microsphere is in the purposes for preparing bleeding-stopping dressing |
| CN109364288B (en) * | 2018-11-26 | 2021-04-02 | 温州生物材料与工程研究所 | Application of hole-hole composite micro-nano structure polysaccharide microspheres in preparation of hemostatic dressing |
| CN110180018A (en) * | 2019-05-24 | 2019-08-30 | 武汉理工大学 | A kind of preparation method of calcic alginate/chitosan hemostatic microsphere |
| CN111632188A (en) * | 2020-06-09 | 2020-09-08 | 湖北精耕生物工程有限公司 | Seaweed polysaccharide composite biological matrix dressing and preparation method thereof |
| CN112755239A (en) * | 2020-12-08 | 2021-05-07 | 上海市肿瘤研究所 | Composite porous microsphere and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103467771B (en) | 2016-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103467771B (en) | A kind of preparation method and its usage of marine bioactivity bleeding-stopping dressing | |
| Fang et al. | 3D porous chitin sponge with high absorbency, rapid shape recovery, and excellent antibacterial activities for noncompressible wound | |
| Wang et al. | Preparation and evaluation of chitosan/alginate porous microspheres/Bletilla striata polysaccharide composite hemostatic sponges | |
| Zhong et al. | Application and outlook of topical hemostatic materials: a narrative review | |
| Li et al. | Preparation and the hemostatic property study of porous gelatin microspheres both in vitro and in vivo | |
| CN103446621B (en) | Preparation method of nano-silver-containing sodium alginate based antibacterial medical dressing | |
| Li et al. | Biodegradable microporous starch with assembled thrombin for rapid induction of hemostasis | |
| CN101584876B (en) | Medical compound micropore polysaccharide and application thereof | |
| CN111632190B (en) | Preparation method of medical biogel hemostatic dressing | |
| CN101991875A (en) | Mesoporous bioactive glass and chitosan composite porous hemostatic material and preparation method thereof | |
| CN106620824A (en) | Preparation method for efficient anti-bacterial composite hemostatic sponge | |
| Cao et al. | Shape memory and antibacterial chitosan-based cryogel with hemostasis and skin wound repair | |
| CN112321885B (en) | Preparation and application of porous material assembled by graphene oxide and chitosan molecules | |
| CN105001434A (en) | Chitosan-based multifunctional hemostasis microsphere | |
| Wang et al. | Multifunctionalized alginate/polydopamine cryogel for hemostasis, antibacteria and promotion of wound healing | |
| Chen et al. | A quaternized chitosan and carboxylated cellulose nanofiber-based sponge with a microchannel structure for rapid hemostasis and wound healing | |
| Zhu et al. | Polysaccharides composite materials for rapid hemostasis | |
| CN107412843B (en) | Starch-based microporous hemostatic material with antibacterial property and preparation method and application thereof | |
| CN101244286A (en) | Hydrogel dressings and preparation thereof | |
| CN104874011A (en) | Hemostatic and preparation method and application thereof | |
| Ren et al. | Antibacterial chitosan-based composite sponge with synergistic hemostatic effect for massive haemorrhage | |
| CN104069535B (en) | A kind of Preparation method and use of biological activity composite membrane bleeding-stopping dressing | |
| CN106540310B (en) | Absorbable rapid hemostatic material and preparation method thereof | |
| CN110975001B (en) | Chitosan-cellulose composite hemostatic sponge and preparation method and application thereof | |
| CN105107006A (en) | Degradable starch-based hemostatic material, preparation method therefor and applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 261061 biomedical science and Technology Park, Gaoxin 2nd Road, high tech Zone, Weifang City, Shandong Province Patentee after: Shandong Mechman biological medicine science and Technology Co.,Ltd. Address before: 261061 biomedical science and Technology Park, Gaoxin 2nd Road, high tech Zone, Weifang City, Shandong Province Patentee before: WEIFANG MEIHEMAN BIOLOGY MEDICAL TECHNOLOGY Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210826 Address after: 261100 plant 2-201, No. 4, No. 8009, Minzhu street, Hanting District, Weifang City, Shandong Province Patentee after: SHANDONG BEINUO MEDICAL BIOLOGY TECHNOLOGY Co.,Ltd. Address before: 261061 biomedical science and Technology Park, Gaoxin 2nd Road, high tech Zone, Weifang City, Shandong Province Patentee before: Shandong Mechman biological medicine science and Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160316 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |